<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title-group><journal-title>BMC Medical Genetics</journal-title></journal-title-group><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-11-38</article-id><article-id pub-id-type="pmid">20196871</article-id><article-id pub-id-type="doi">10.1186/1471-2350-11-38</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title><italic>PARP-1 </italic>Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Jin</surname><given-names>Xue Mei</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>yjjxm@hanmail.net</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Kim</surname><given-names>Hee Nam</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kimhnamx@paran.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Lee</surname><given-names>Il-Kwon</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ellerdine@paran.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Park</surname><given-names>Kyeong-Soo</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>pys0903@hitel.net</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Kim</surname><given-names>Hyeoung-Joon</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>hjoonk@chonnam.ac.kr</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Choi</surname><given-names>Jin-Su</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>jschoix@jnu.ac.kr</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Juhng</surname><given-names>Sang Woo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>swjuhng@jnu.ac.kr</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Choi</surname><given-names>Chan</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>cchoi@chonnam.ac.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, 160, Ilsim-ni, Hwasun-eup, Hwasun-gun, Chonnam, 519-809, Republic of Korea</aff><aff id="I2"><label>2</label>Department of Pathology, Chonnam National University Medical School, 5 Hak-dong, Dong-gu, Gwangju, 501-746, Republic of Korea</aff><aff id="I3"><label>3</label>Department of Hematology/Oncology, Chonnam National University Medical School, 5 Hak-dong, Dong-gu, Gwangju, 501-746, Republic of Korea</aff><aff id="I4"><label>4</label>Department of Preventive Medicine, Chonnam National University Medical School, 5 Hak-dong, Dong-gu, Gwangju, 501-746, Republic of Korea</aff><aff id="I5"><label>5</label>Department of Preventive Medicine, College of Medicine, Seonam University, 720 Gwangchi-dong, Namwon, 590-711, Republic of Korea</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2010</year></pub-date><volume>11</volume><fpage>38</fpage><lpage>38</lpage><history><date date-type="received"><day>29</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Jin et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Jin et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2350/11/38"/><abstract><sec><title>Background</title><p>Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a role in DNA repair, differentiation, proliferation, and cell death. The polymorphisms of <italic>PARP-1 </italic>have been associated with the risk of various carcinomas, including breast, lung, and prostate. We investigated whether <italic>PARP-1 </italic>polymorphisms are associated with the risk of non-Hodgkin lymphoma (NHL).</p></sec><sec><title>Methods</title><p>Subjects from a Korean population consisting of 573 NHL patients and 721 controls were genotyped for 5 <italic>PARP-1 </italic>polymorphisms (Asp81Asp, Ala284Ala, Lys352Lys, IVS13+118A&#x0003e;G, and Val762Ala) using High Resolution Melting polymerase chain reaction (PCR) and an automatic sequencer.</p></sec><sec><title>Results</title><p>None of the 5 polymorphisms were associated with overall risk for NHL. However, the Val762Ala polymorphism was associated with reduced risk for NHL in males [odds ratio (OR), 0.62; 95% confidence interval (CI), 0.41-0.93 for CC genotype and OR, 0.84; 95% CI, 0.60-1.16 for TC genotype] with a trend toward a gene dose effect (p for trend, 0.02). The Asp81Asp (p for trend, 0.04) and Lys352Lys (p for trend, 0.03) polymorphisms revealed the same trend. In an association study of <italic>PARP-1 </italic>haplotypes, the haplotype-ACAAC was associated with decreased risk of NHL in males (OR, 0.75; 95% CI, 0.59-0.94).</p></sec><sec><title>Conclusion</title><p>The present data suggest that Val762Ala, Asp81Asp, and Lys352Lys polymorphisms and the haplotype-ACAAC in <italic>PARP-1 </italic>are associated with reduced risk of NHL in Korean males.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy worldwide. It represents 4% of cancers, and is the fifth commonly diagnosed cancer in the United States [<xref ref-type="bibr" rid="B1">1</xref>]. Its rates are over 10/100,000 in the United States, Australia, and Western Europe, while less than 5/100,000 in Southern and Eastern Asia [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>PARP-1 is a nuclear enzyme that catalyzes the poly(ADP-ribosyl)ation of target proteins in response to DNA damage; it is involved in DNA repair, cell death, proliferation, genome integrity, and modulation of gene transcription [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. PARP-1 is involved in base excision reaction, which repairs DNA damage induced by chemical alterations, reactive oxidative species, and ionizing radiation. In addition, PARP-1 activation mediates apoptosis through the induction of translocation of apoptosis-inducing factor from the mitochondria to the nucleus [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>The effect of PARP-1 on carcinogenesis is still unclear and controversial. PARP-1 activation has been reported to inhibit carcinogenesis by activation of DNA repair system [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. <italic>Parp </italic>deficiencies have enhanced tumorigenesis and widened the tumor spectrum in <italic>p53-</italic>deficient mice [<xref ref-type="bibr" rid="B10">10</xref>]. Treatment with the alkylating agent, azoxymethane, enhanced the frequency of tumor development in the colon and liver of <italic>Parp</italic>-1<sup>-/- </sup>mice [<xref ref-type="bibr" rid="B9">9</xref>]. Studies have demonstrated that <italic>PARP-1 </italic>Val762Ala polymorphism is associated with an increased risk of carcinomas, including prostate [<xref ref-type="bibr" rid="B8">8</xref>], esophagus [<xref ref-type="bibr" rid="B7">7</xref>], lung [<xref ref-type="bibr" rid="B12">12</xref>], stomach [<xref ref-type="bibr" rid="B11">11</xref>], breast [<xref ref-type="bibr" rid="B13">13</xref>], and urinary bladder [<xref ref-type="bibr" rid="B6">6</xref>]. In contrast, others have reported that inhibition or the absence of PARP-1 is associated with reduced risk of malignancy by inducing tumor cell apoptosis [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Loss of <italic>Parp-1 </italic>has increased tumor latency in <italic>p53</italic>-deficient mice [<xref ref-type="bibr" rid="B14">14</xref>]. <italic>Parp-1</italic><sup>-/- </sup>mice displayed a diminished susceptibility to skin carcinogenesis compared with <italic>Parp-1</italic><sup>+/+ </sup>mice after treatment with 7,12-dimethylbenz [a]-anthracene and 12-O-tetra-decanoyl-phorbol-13-acetate [<xref ref-type="bibr" rid="B17">17</xref>]. <italic>PARP-1 </italic>polymorphisms have been associated with reduced risk of malignancy in several case-control studies [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. However, others have also proposed that PARP-1 has no effects on tumor development [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. <italic>Parp-1</italic><sup>-/- </sup>mice did not demonstrate an increased incidence of tumor formation after either 4-nitroso-quinoline or 2-amino-3-methylimidazo treatment [<xref ref-type="bibr" rid="B19">19</xref>]. In a case-control study in Connecticut women, the risk of NHL was not associated with <italic>PARP-1 </italic>Val762Ala polymorphism [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Although many studies have searched for the association between PARP-1 polymorphisms and the risk of malignancy, the results are inconsistent in different organs and in different ethnic groups. We performed a population-based, case-control study to identify the association between <italic>PARP-1 </italic>polymorphisms and NHL risk in Korean subjects.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>This case-control study included NHL patients (n = 573) and cancer-free controls (n = 721). All cases and controls were unrelated Korean individuals; the cases were adults (median age at diagnosis &#x000b1; S.D 55.0 &#x000b1; 14.6 years, range 15.0-90.0 years), histologically diagnosed with NHL between 1997 and 2006 at Chonnam National University Hospital (Gwangju, Korea) or Chonnam National University Hwasun Hospital (Hwasun, Korea) [<xref ref-type="bibr" rid="B21">21</xref>]. Lymph nodes or extranodal tissues were obtained and histologically diagnosed according to the World Health Organization (WHO) classification [<xref ref-type="bibr" rid="B22">22</xref>]. A staging workup included physical examination, laboratory examination, computed tomography scan, bone marrow biopsy, and lumbar puncture. Stages were defined according to the Ann Arbor system [<xref ref-type="bibr" rid="B23">23</xref>]. Types of NHL included diffuse large B-cell lymphomas (n = 330), T-cell lymphomas (n = 122), and other lymphomas (n = 121). The controls were frequency matched to patients by age within 5 years, sex, and county of residence. All of the healthy controls have no history of cancer (427 males, 304 females; median age &#x000b1; S.D. 56.0 &#x000b1; 15.3 years, range 17.0-82.5 years) (Table <xref ref-type="table" rid="T1">1</xref>). All cases and controls provided informed consent for study participation. The study was approved by the Institutional Review Board of the Chonnam National University Hwasun Hospital in Hwasun, Korea.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Frequency distribution of selected characteristics of study subjects According to case-control status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="right">Cases</th><th align="center">Controls</th><th align="center"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left">No.(%)</td><td align="right">573 (100)</td><td align="center">721 (100)</td><td/></tr><tr><td align="left">Age, no.(%)</td><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;15-49 y</td><td align="right">179 (31.2)</td><td align="center">201 (27.9)</td><td/></tr><tr><td align="left">&#x02003;&#x02003;50-64 y</td><td align="right">226 (39.4)</td><td align="center">286 (39.7</td><td/></tr><tr><td align="left">&#x02003;&#x02003;&#x02265; 65 y</td><td align="right">168 (29.3)</td><td align="center">234 (32.5)</td><td align="center">0.33</td></tr><tr><td align="left">&#x02003;Mean(yr.) &#x000b1; SD</td><td align="right">55.0 &#x000b1; 14.6</td><td align="center">56.0 &#x000b1; 15.3</td><td/></tr><tr><td align="left">&#x02003;Range</td><td align="right">15.0-90.0</td><td align="center">17.0-82.5</td><td/></tr><tr><td align="left">Sex</td><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="right">336 (58.6)</td><td align="center">417 (57.8)</td><td/></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="right">237 (41.4)</td><td align="center">304 (42.2)</td><td align="center">0.77</td></tr><tr><td align="left">NHL tumor pathology</td><td/><td/><td/></tr><tr><td align="left">&#x02003;All B-cell lymphoma</td><td align="right">451</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Diffuse large B-cell</td><td align="right">330</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Marginal zone*</td><td align="right">69</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Follicular</td><td align="right">17</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mantle cell</td><td align="right">12</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Small lymphocytic</td><td align="right">8</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Burkitt lymphoma</td><td align="right">3</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Others<sup>B</sup></td><td align="right">12</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;All T-cell lymphoma</td><td align="right">122</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Peripheral T-cell</td><td align="right">55</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Others<sup>T</sup></td><td align="right">67</td><td align="center">NA</td><td align="center">NA</td></tr></tbody></table><table-wrap-foot><p><italic>P </italic>values for differences in socio-demographic characteristics between cases and controls.</p><p>NA indicates not applicable. Marginal zone* includes marginal zone B-cell lymphoma (n = 12) and mucosa-associated lymphoid tissue (MALT) (n = 57). Others<sup>B </sup>includes B-cell prolymphocytic leukemia (n = 1) and undetermined B-cell lymphoma (n = 11). Others<sup>T </sup>includes all T-cell lymphoma (n = 67) except for peripheral T-cell lymphoma.</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping</title><p>Genomic DNA was obtained from peripheral blood using a QIAamp DNA Blood Mini Kits (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols. PCR cycling and high resolution melting (HRM) analysis was performed on the Rotor-Gene 6000&#x02122; (Corbett Research, Sydney, Australia) [<xref ref-type="bibr" rid="B24">24</xref>]. The PCR primers were as follows: for Val762Ala (86 bp fragment), 5'-taagtcgggggctttctttt-3' (forward), and 5'-agcagactgtaggccacctc-3' (reverse); for Asp81Asp (160 bp fragment), 5'-gatgggttctctgagcttcg-3' (forward), and 5'-gaggtttgctttgctctctga-3' (reverse); for Ala284Ala (76 bp fragment), 5'-gccctctgacatgtttctcc-3' (forward), and 5'-aaggagggcaccgaacac-3' (reverse); for Lys352Lys (178 bp fragment), 5'-caagggagagctggcttctt-3' (forward), and 5'-ggagttcacagcagcagga-3' (reverse); for IVS13+118A&#x0003e;G (124 bp fragment), 5'-tggatcaggtggcatcatag-3' (forward), and 5'-ggtactggccttcatgcaat-3' (reverse). The reaction mixture included genomic DNA (10 ng), 1&#x000d7; PCR buffer, 2.5 mM MgCl<sub>2</sub>, primers (100 nM), dNTPs (100 &#x003bc;M), SYTO 9 green fluorescent nucleic acid stain (2.5 &#x003bc;M; Invitrogen, Carlsbad, CA, USA), Taq. polymerase (0.5 U; Solgent, Daejeon, Korea) and water to a total volume of 10 &#x003bc;l. Cycling conditions included an initial 5 min hold at 95&#x000b0;C, followed by 40 cycles at 95&#x000b0;C for 5 s, annealing temperatures for 30 s, and 72&#x000b0;C for 20 s; a single cycle of 95&#x000b0;C for 1 s, 72&#x000b0;C for 90 s, and melting increasing from 70&#x000b0;C to 90&#x000b0;C at 0.1&#x000b0;C per second. Annealing temperatures for Asp81Asp, Ala284Ala, Lys352Lys, Val762Ala and IVS13+118A&#x0003e;G were 62&#x000b0;C, 56&#x000b0;C, 58&#x000b0;C, 56&#x000b0;C, and 60&#x000b0;C, respectively.</p><p>PCR products were column-purified after HRM analysis using the PCR-M clean up kit (GeneAll Biotechnology, Seoul, Korea) according to the manufacturer's instructions. PCR products were eluted in a 20 &#x003bc;l volume, purified PCR products were used as templates in the Big Dye Terminator v3.1 Cycling Sequencing kit (Applied Biosystems, Foster City, CA, USA). The reaction mix consisted of 1&#x000d7; terminator pre-mix, 1&#x000d7; sequencing buffer, primers (667 nM), and purified template (1 &#x003bc;l) in a 10 &#x003bc;l total volume. Reactions were run on a PTC-100 thermal cycler (MJ Research, Reno, NV, USA) as follows: a single cycle of 95&#x000b0;C for 1 min, 25 cycles of 95&#x000b0;C for 10 s, 50&#x000b0;C for 5 s, and 60&#x000b0;C for 4 min. Sequencing reactions were ethanol-precipitated and run on a 3100 Genetic Analyser (Applied Biosystems). In 90 subjects, the results of HRM analyses were compared with those from cycle sequencing, and the resulting concordance rate was 100%.</p></sec><sec><title>Statistical analysis</title><p>Hardy-Weinberg equilibrium testing was performed using the chi-square goodness-of-fit test. The Pearson chi-square test was used to examine the genotype distribution differences between cases and controls. Adjusted odds ratios (ORs) were calculated using a logistic regression model that controlled for gender and age and included 95% confidence intervals (CIs). Statistical significance was defined at <italic>p </italic>values less than 0.05, and all statistical tests were 2-sided. Haplotypes and haplotype frequencies were calculated using the SNPAnalyzer-Pro version 1.8 software (Istech, Goyang, Korea) to analyze associations between haplotypes and NHL risk after stratification by age at diagnosis, sex, and NHL subtype. All calculations were performed using an SPSS software package, version 13.0 (SPSS, Chicago, IL). <italic>PARP-1 </italic>inter-SNP linkage disequilibrium was calculated using Haploview software version 4.1 <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview">http://www.broad.mit.edu/mpg/haploview</ext-link> for the set of control samples (n = 721).</p></sec></sec><sec><title>Results</title><p>Characteristics of the study population are summarized in Table <xref ref-type="table" rid="T1">1</xref>. There were no differences in the frequency distribution for age (<italic>p </italic>= 0.33) or sex (<italic>p </italic>= 0.77) between cases and controls. The control genotype distributions were in agreement with the Hardy-Weinberg equilibrium (<italic>p </italic>= 0.61 for Asp81Asp, <italic>p </italic>= 0.31 for Ala284Ala, <italic>p </italic>= 0.83 for Lys352Lys, <italic>p </italic>= 0.38 for IVS13+118 A&#x0003e;G, <italic>p </italic>= 0.84 for Val762Ala). Haploview version 4.1 determined that the <italic>PARP-1 </italic>locus contained 1 block of linkage disequilibrium (Figure. <xref ref-type="fig" rid="F1">1</xref>). Two groups of polymorphisms were present in the block; one group consisted of Asp81Asp, Lys352Lys, and Val762Ala polymorphism, and the other included Ala284Ala and IVS13+118A&#x0003e;G polymorphism. Both revealed high intra-group linkage disequilibrium (r<sup>2</sup>, &#x02265; 0.96), but low inter-group linkage disequilibrium (r<sup>2</sup>, 0.22-0.23).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold><italic>PARP-1 </italic>inter-polymorphism linkage disequilibrium</bold>. <italic>PARP-1 </italic>inter-polymorphism linkage disequilibrium. r<sup>2 </sup>between pairs of polymorphisms was calculated based on all the controls using Haploview v4.1 <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview">http://www.broad.mit.edu/mpg/haploview</ext-link>.</p></caption><graphic xlink:href="1471-2350-11-38-1"/></fig><p>Table <xref ref-type="table" rid="T2">2</xref> summarizes the association study between the 5 polymorphisms and the overall risk for NHL. Analysis revealed no significant associations between polymorphisms and overall NHL risk. Neither the CC genotype of Val762Ala (OR, 0.85; 95%CI, 0.62-1.17) nor the TC genotype (OR, 0.93; 95%CI, 0.72-1.19) were associated with risk for NHL. The genotypes of the remaining 4 polymorphisms were also associated with risk for NHL.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Association testing of <italic>PARP-1 </italic>polymorphisms with risk of NHL</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">NPs</th><th align="left">Genotype</th><th align="left">Controls<break/>no.(%)</th><th align="left">Cases<break/>no.(%)</th><th align="center">OR (95% CI)</th></tr></thead><tbody><tr><td align="left">Asp81Asp</td><td align="left">GG</td><td align="left">227 (31.5)</td><td align="left">185 (32.5)</td><td align="center">1</td></tr><tr><td/><td align="left">GA</td><td align="left">349 (48.4)</td><td align="left">279 (49.0)</td><td align="center">0.99 (0.77-1.27)</td></tr><tr><td/><td align="left">AA</td><td align="left">145 (20.1)</td><td align="left">105 (18.5)</td><td align="center">0.90 (0.65-1.24)</td></tr><tr><td/><td align="left">GA+AA</td><td align="left">494 (68.5)</td><td align="left">384 (67.5)</td><td align="center">0.96 (0.76-1.21)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align="left">Ala284Ala</td><td align="left">CC</td><td align="left">424 (58.8)</td><td align="left">357 (62.4)</td><td align="center">1</td></tr><tr><td/><td align="left">CT</td><td align="left">264 (36.6)</td><td align="left">189 (33.0)</td><td align="center">0.85 (0.67-1.07)</td></tr><tr><td/><td align="left">TT</td><td align="left">33 (4.6)</td><td align="left">26 (4.5)</td><td align="center">0.94 (0.55-1.60)</td></tr><tr><td/><td align="left">CT+TT</td><td align="left">297 (41.2)</td><td align="left">215 (37.6)</td><td align="center">0.86 (0.69-1.08)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align="left">Lys352Lys</td><td align="left">GG</td><td align="left">222 (30.8)</td><td align="left">184 (32.1)</td><td align="center">1</td></tr><tr><td/><td align="left">GA</td><td align="left">353 (49.0)</td><td align="left">285 (49.7)</td><td align="center">0.98 (0.76-1.26)</td></tr><tr><td/><td align="left">AA</td><td align="left">145 (20.1)</td><td align="left">104 (18.2)</td><td align="center">0.87 (0.64-1.20)</td></tr><tr><td/><td align="left">GA+AA</td><td align="left">498 (69.2)</td><td align="left">389 (67.9)</td><td align="center">0.95 (0.75-1.20)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align="left">IVS13+118 A&#x0003e;G</td><td align="left">AA</td><td align="left">426 (59.2)</td><td align="left">361 (63.0)</td><td align="center">1</td></tr><tr><td/><td align="left">AG</td><td align="left">261 (36.3)</td><td align="left">188 (32.8)</td><td align="center">0.85 (0.67-1.07)</td></tr><tr><td/><td align="left">GG</td><td align="left">33 (4.6)</td><td align="left">24 (4.2)</td><td align="center">0.86 (0.50-1.48)</td></tr><tr><td/><td align="left">AG+GG</td><td align="left">294 (40.8)</td><td align="left">212 (37.0)</td><td align="center">0.85 (0.68-1.06)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align="left">Val762Ala</td><td align="left">TT</td><td align="left">221 (30.7)</td><td align="left">189 (33.0)</td><td align="center">1</td></tr><tr><td/><td align="left">TC</td><td align="left">354 (49.1)</td><td align="left">279 (48.7)</td><td align="center">0.93 (0.72-1.19)</td></tr><tr><td/><td align="left">CC</td><td align="left">146 (20.2)</td><td align="left">105 (18.3)</td><td align="center">0.85 (0.62-1.17)</td></tr><tr><td/><td align="left">TC+CC</td><td align="left">500 (69.3)</td><td align="left">384 (67.0)</td><td align="center">0.90 (0.71-1.14)</td></tr></tbody></table><table-wrap-foot><p>All analyses have been age- and sex-adjusted. <italic>P </italic>values were &#x0003e; 0.05 in all analyses.</p></table-wrap-foot></table-wrap><p>As presented in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: table S1, males with the TC genotype of Val762Ala demonstrated a slightly reduced NHL risk (OR, 0.84; 95% CI, 0.60-1.16) compared to those with the TT genotype. And the males with the CC genotype had a significantly reduced risk (OR, 0.62; 95% CI, 0.41-0.93) which revealed a trend toward a gene dose effect (p for trend, 0.02). However, there was no association between Val762Ala polymorphism and NHL risk in females. There was significant interaction seen between sex and the Val762Ala polymorphism (p for interaction, 0.048). Asp81Asp (p for trend, 0.04) and Lys352Lys (p for trend, 0.03) polymorphisms revealed similar trends, although interactions between sex and polymorphism were a borderline significance levels (p for interaction of Asp81Asp, 0.062; p for interaction of Lys352Lys, 0.067). However, <italic>PARP-1 </italic>polymorphisms did not show associations with the NHL subtypes (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: table S2) or age (data not shown).</p><p>The distribution of <italic>PARP-1 </italic>haplotype frequencies and association of haplotypes with risk for NHL are summarized in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: table S3. Three common haplotypes (ACAAC, GCGAT, and GTGGT) and several rare ones (with frequency &#x0003c; 5%) were inferred, and rare haplotypes were excluded in the association analyses. None of the haplotypes were associatied with overall risk for NHL. However the haplotype-ACAAC in males was associated with decreased risk for NHL (OR, 0.74; 95% CI, 0.59-0.94) when haplotype-GCGAT was used as a reference.</p></sec><sec><title>Discussion</title><p>We investigated the association between 5 <italic>PARP-1 </italic>polymorphisms and NHL risk in a Korean population. Three polymorphisms (Asp81Asp, Lys352Lys, and Val762Ala) were associated with decreased risk of NHL in males. A association testing of haplotype-ACAAC revealed a similar result. However, none of the <italic>PARP-1 </italic>polymorphisms or haplotypes were associated with overall NHL risk.</p><p>Our data appear to support the hypothesis that accumulated DNA damage may lead to enhanced apoptosis during cell division, which could result in protection from development of malignancy with intact apoptotic mechanisms. Concordant findings with the results of this study have been identified in case-control studies of squamous cell carcinoma of the head and neck [<xref ref-type="bibr" rid="B15">15</xref>], breast carcinoma [<xref ref-type="bibr" rid="B18">18</xref>], and adult glioma [<xref ref-type="bibr" rid="B16">16</xref>]. In animal experiments, overexpression of dominant negative PARP-1 prevented <italic>in vivo </italic>tumor formation by HeLa cells in nude mice due to increased apoptosis of tumor cells [<xref ref-type="bibr" rid="B25">25</xref>].</p><p><italic>PARP-1 </italic>polymorphisms were associated with decreased risk of NHL in males in this study. The sexual dimorphism might be associated with the female sex hormone, 17-&#x003b2;-estradiol. PARP strongly interacts with estrogen receptor &#x003b1; and DNA in the presence of 17-&#x003b2;-estradiol, which leads to inhibition of PARP activation [<xref ref-type="bibr" rid="B26">26</xref>]. Sex-dependent response to PARP activation has also been reported in an endotoxin-induced inflammation and vascular change model, female mice were more resistant to endotoxin than male mice[<xref ref-type="bibr" rid="B26">26</xref>]. In a neonatal-stroke mouse model, disruption of the <italic>PARP-1 </italic>gene selectively protected male mice against brain injury [<xref ref-type="bibr" rid="B27">27</xref>]. Also in an adult-stroke mouse model, female neuronal nitric oxide synthase knockout (nNOS-/-) mice were more severely damaged after middle cerebral artery occlusion than wild-type females. In addition, male nNOS-/- littermates were protected [<xref ref-type="bibr" rid="B28">28</xref>]. In a case-control study, <italic>PARP-1 </italic>polymorphism has been associated with reduced risk of adult glioma in men [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Inconsistency of the association between <italic>PARP-1 </italic>polymorphism and malignancy risk might result from differences in genetic background, environmental factors, organ specificity, and study sample size. For example, the frequency of the Val762Ala genetic polymorphism differs between ethnic groups. In the present study of Koreans, the frequency of the C allele is 0.448 which is consistent with that observed in previous studies of Koreans (0.444) and Han Chinese (0.389) [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. However, the frequency is 0.145 in Caucasian-Americans and 0.045 among African-Americans [<xref ref-type="bibr" rid="B8">8</xref>]. PARP-1 expression levels vary in carcinomas of different organs. It is high in lymphoma [<xref ref-type="bibr" rid="B30">30</xref>] and endometrial carcinoma [<xref ref-type="bibr" rid="B31">31</xref>], and low in breast carcinoma [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>] and laryngeal carcinoma [<xref ref-type="bibr" rid="B34">34</xref>].</p><p>In this present study, haplotype-ACAAC was also associated with reduced risk of NHL in males, although there was no association between any haplotypes and overall NHL risk. It agrees with the results that the A allele of Asp81Asp, A allele of Lys352Lys, and C allele of Val762Ala are significantly associated with decreased risk of NHL.</p><p>As the sample size of this study is not sufficiently large and is restricted to Korean population, the present data should be validated in larger samples and in other ethnic groups. Although <italic>PARP-1 </italic>polymorphisms are associated with decreased risk of NHL in the present study, we could not exclude the possibility that other un-typed variants located in or near the <italic>PARP-1 </italic>locus might be associated with reduced risk of NHL. Additional surveys examining other variants around the locus are required to resolve this issue. A gene-gene interaction study examining genes involved in apoptosis or DNA repair might allow for a more comprehensive perspective.</p></sec><sec><title>Conclusion</title><p>In a polulation-based, case-control study to identify the association between polymorphisms in <italic>PARP-1 </italic>and NHL risk in Koreans, we found that Val762Ala, Asp81Asp, and Lys352Lys polymorphisms and the haplotype-ACAAC in <italic>PARP-1 </italic>were associated with decreased risk of NHL in males.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All authors read and approved the final version to be published. XMJ carried out genotyping and drafted the manuscript. HNK participated in sequence alignment. IKL involved in drafting the manuscript and revising it critically. KSP did statistical analysis of the data. HJK have given final approval of the version to be published. JSC collected the control samples and advised in data analysis. SWJ designed of the study. CC designed the study and helped to draft the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/11/38/prepub">http://www.biomedcentral.com/1471-2350/11/38/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Supplemental tables S1, S2 and S3.</p></caption><media xlink:href="1471-2350-11-38-S1.DOCX" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>This study was supported by a grant from the Korea Health 21 R&#x00026;D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ10-PG6-01GN16-0005).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Muller</surname><given-names>AM</given-names></name><name><surname>Ihorst</surname><given-names>G</given-names></name><name><surname>Mertelsmann</surname><given-names>R</given-names></name><name><surname>Engelhardt</surname><given-names>M</given-names></name><article-title>Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology</article-title><source>Ann Hematol</source><year>2005</year><volume>84</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s00277-004-0939-7</pub-id><pub-id pub-id-type="pmid">15480663</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><source>World cancer report 2008</source><year>2008</year><publisher-name>Lyon: International Agency for Research on Cancer</publisher-name><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">18347028</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Herceg</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><article-title>Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death</article-title><source>Mutat Res</source><year>2001</year><volume>477</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">11376691</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Lindahl</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>MS</given-names></name><name><surname>Poirier</surname><given-names>GG</given-names></name><name><surname>Klungland</surname><given-names>A</given-names></name><article-title>Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks</article-title><source>Trends Biochem Sci</source><year>1995</year><volume>20</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(00)89089-1</pub-id><pub-id pub-id-type="pmid">8533153</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>SW</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Poitras</surname><given-names>MF</given-names></name><name><surname>Coombs</surname><given-names>C</given-names></name><name><surname>Bowers</surname><given-names>WJ</given-names></name><name><surname>Federoff</surname><given-names>HJ</given-names></name><name><surname>Poirier</surname><given-names>GG</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><article-title>Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1126/science.1072221</pub-id><pub-id pub-id-type="pmid">12114629</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Figueroa</surname><given-names>JD</given-names></name><name><surname>Malats</surname><given-names>N</given-names></name><name><surname>Real</surname><given-names>FX</given-names></name><name><surname>Silverman</surname><given-names>D</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Dosemeci</surname><given-names>M</given-names></name><name><surname>Tardon</surname><given-names>A</given-names></name><name><surname>Serra</surname><given-names>C</given-names></name><article-title>Genetic variation in the base excision repair pathway and bladder cancer risk</article-title><source>Hum Genet</source><year>2007</year><volume>121</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/s00439-006-0294-y</pub-id><pub-id pub-id-type="pmid">17203305</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Hao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><article-title>Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>4378</fpage><lpage>4384</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0372</pub-id><pub-id pub-id-type="pmid">15205355</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Lockett</surname><given-names>KL</given-names></name><name><surname>Hall</surname><given-names>MC</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Chuang</surname><given-names>SC</given-names></name><name><surname>Clark</surname><given-names>PE</given-names></name><name><surname>Cramer</surname><given-names>SD</given-names></name><name><surname>Lohman</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>JJ</given-names></name><article-title>The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>6344</fpage><lpage>6348</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0338</pub-id><pub-id pub-id-type="pmid">15342424</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Fujihara</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Tsutsumi</surname><given-names>M</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Kusuoka</surname><given-names>O</given-names></name><name><surname>Kamada</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Nakagama</surname><given-names>H</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><article-title>Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane</article-title><source>Cancer Sci</source><year>2003</year><volume>94</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01472.x</pub-id><pub-id pub-id-type="pmid">12824873</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Tong</surname><given-names>WM</given-names></name><name><surname>Cortes</surname><given-names>U</given-names></name><name><surname>Hande</surname><given-names>MP</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Cavalli</surname><given-names>LR</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Haddad</surname><given-names>BR</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><article-title>Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>6990</fpage><lpage>6996</lpage><pub-id pub-id-type="pmid">12460917</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><article-title>PARP-1 Val762Ala polymorphism, CagA+ H. pylori infection and risk for gastric cancer in Han Chinese population</article-title><source>Mol Biol Rep</source><year>2009</year><volume>36</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1007/s11033-008-9336-y</pub-id><pub-id pub-id-type="pmid">18716896</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Hao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><article-title>Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>722</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">15705867</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Miao</surname><given-names>XP</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>XM</given-names></name><name><surname>Lin</surname><given-names>DX</given-names></name><article-title>[Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer]</article-title><source>Ai Zheng</source><year>2006</year><volume>25</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16405741</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Conde</surname><given-names>C</given-names></name><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Oliver</surname><given-names>FJ</given-names></name><name><surname>Huber</surname><given-names>A</given-names></name><name><surname>de Murcia</surname><given-names>G</given-names></name><name><surname>Menissier-de Murcia</surname><given-names>J</given-names></name><article-title>Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>3535</fpage><lpage>3543</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.13.3535</pub-id><pub-id pub-id-type="pmid">11432840</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>LE</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Sturgis</surname><given-names>EM</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><article-title>Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck</article-title><source>Cancer</source><year>2007</year><volume>110</volume><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1002/cncr.22861</pub-id><pub-id pub-id-type="pmid">17614107</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Scheurer</surname><given-names>ME</given-names></name><name><surname>El-Zein</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Do</surname><given-names>KA</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Etzel</surname><given-names>C</given-names></name><name><surname>Bondy</surname><given-names>ML</given-names></name><article-title>Association and interactions between DNA repair gene polymorphisms and adult glioma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2009</year><volume>18</volume><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0632</pub-id><pub-id pub-id-type="pmid">19124499</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Martin-Oliva</surname><given-names>D</given-names></name><name><surname>O'Valle</surname><given-names>F</given-names></name><name><surname>Munoz-Gamez</surname><given-names>JA</given-names></name><name><surname>Valenzuela</surname><given-names>MT</given-names></name><name><surname>Nunez</surname><given-names>MI</given-names></name><name><surname>Aguilar</surname><given-names>M</given-names></name><name><surname>Ruiz de Almodovar</surname><given-names>JM</given-names></name><name><surname>Garcia del Moral</surname><given-names>R</given-names></name><name><surname>Oliver</surname><given-names>FJ</given-names></name><article-title>Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>5275</fpage><lpage>5283</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207696</pub-id><pub-id pub-id-type="pmid">15077172</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Levine</surname><given-names>EA</given-names></name><name><surname>Freimanis</surname><given-names>RI</given-names></name><name><surname>Akman</surname><given-names>SA</given-names></name><name><surname>Allen</surname><given-names>GO</given-names></name><name><surname>Hoang</surname><given-names>KN</given-names></name><name><surname>Liu-Mares</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>JJ</given-names></name><article-title>Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>2132</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn193</pub-id><pub-id pub-id-type="pmid">18701435</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Masutani</surname><given-names>M</given-names></name><name><surname>Nakagama</surname><given-names>H</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><article-title>Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease</article-title><source>Cell Mol Life Sci</source><year>2005</year><volume>62</volume><fpage>769</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1007/s00018-004-4509-x</pub-id><pub-id pub-id-type="pmid">15868402</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zahm</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>SS</given-names></name><name><surname>Holford</surname><given-names>TR</given-names></name><name><surname>Leaderer</surname><given-names>B</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><article-title>Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut</article-title><source>Hum Genet</source><year>2006</year><volume>119</volume><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1007/s00439-006-0177-2</pub-id><pub-id pub-id-type="pmid">16738949</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>HN</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>MR</given-names></name><name><surname>Jo</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><article-title>Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma</article-title><source>Am J Hematol</source><year>2007</year><volume>82</volume><fpage>798</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1002/ajh.20967</pub-id><pub-id pub-id-type="pmid">17546637</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name><source>World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues</source><year>2001</year><publisher-name>Lyon: IARC Press</publisher-name></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Lister</surname><given-names>TA</given-names></name><name><surname>Crowther</surname><given-names>D</given-names></name><name><surname>Sutcliffe</surname><given-names>SB</given-names></name><name><surname>Glatstein</surname><given-names>E</given-names></name><name><surname>Canellos</surname><given-names>GP</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Coltman</surname><given-names>CA</given-names></name><name><surname>Tubiana</surname><given-names>M</given-names></name><article-title>Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1630</fpage><lpage>1636</lpage><pub-id pub-id-type="pmid">2809679</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Polakova</surname><given-names>KM</given-names></name><name><surname>Lopotova</surname><given-names>T</given-names></name><name><surname>Klamova</surname><given-names>H</given-names></name><name><surname>Moravcova</surname><given-names>J</given-names></name><article-title>High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain</article-title><source>Leuk Res</source><year>2008</year><volume>32</volume><fpage>1236</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2008.01.010</pub-id><pub-id pub-id-type="pmid">18308387</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Hans</surname><given-names>MA</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Meyer-Ficca</surname><given-names>M</given-names></name><name><surname>Burkle</surname><given-names>A</given-names></name><name><surname>Kupper</surname><given-names>JH</given-names></name><article-title>Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>7010</fpage><lpage>7015</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203178</pub-id><pub-id pub-id-type="pmid">10597301</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Mabley</surname><given-names>JG</given-names></name><name><surname>Horvath</surname><given-names>EM</given-names></name><name><surname>Murthy</surname><given-names>KG</given-names></name><name><surname>Zsengeller</surname><given-names>Z</given-names></name><name><surname>Vaslin</surname><given-names>A</given-names></name><name><surname>Benko</surname><given-names>R</given-names></name><name><surname>Kollai</surname><given-names>M</given-names></name><name><surname>Szabo</surname><given-names>C</given-names></name><article-title>Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation</article-title><source>J Pharmacol Exp Ther</source><year>2005</year><volume>315</volume><fpage>812</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1124/jpet.105.090480</pub-id><pub-id pub-id-type="pmid">16079296</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Hagberg</surname><given-names>H</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name><name><surname>Matsushita</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Gustavsson</surname><given-names>M</given-names></name><name><surname>Poitras</surname><given-names>MF</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Northington</surname><given-names>F</given-names></name><article-title>PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury</article-title><source>J Neurochem</source><year>2004</year><volume>90</volume><fpage>1068</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02547.x</pub-id><pub-id pub-id-type="pmid">15312162</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>McCullough</surname><given-names>LD</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Blizzard</surname><given-names>KK</given-names></name><name><surname>Debchoudhury</surname><given-names>I</given-names></name><name><surname>Hurn</surname><given-names>PD</given-names></name><article-title>Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection</article-title><source>J Cereb Blood Flow Metab</source><year>2005</year><volume>25</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600059</pub-id><pub-id pub-id-type="pmid">15689952</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jeon</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>GY</given-names></name><name><surname>Park</surname><given-names>RW</given-names></name><name><surname>Kam</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>IS</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Jheon</surname><given-names>SH</given-names></name><article-title>No association between haplotypes of three variants (codon 81, 284, and 762) in poly(ADP-ribose) polymerase gene and risk of primary lung cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2003</year><volume>12</volume><fpage>947</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">14504211</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Tomoda</surname><given-names>T</given-names></name><name><surname>Kurashige</surname><given-names>T</given-names></name><name><surname>Moriki</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Fujimoto</surname><given-names>S</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><article-title>Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma</article-title><source>Am J Hematol</source><year>1991</year><volume>37</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830370402</pub-id><pub-id pub-id-type="pmid">1907096</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Ghabreau</surname><given-names>L</given-names></name><name><surname>Roux</surname><given-names>JP</given-names></name><name><surname>Frappart</surname><given-names>PO</given-names></name><name><surname>Mathevet</surname><given-names>P</given-names></name><name><surname>Patricot</surname><given-names>LM</given-names></name><name><surname>Mokni</surname><given-names>M</given-names></name><name><surname>Korbi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Tong</surname><given-names>WM</given-names></name><name><surname>Frappart</surname><given-names>L</given-names></name><article-title>Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors</article-title><source>Int J Cancer</source><year>2004</year><volume>109</volume><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1002/ijc.11731</pub-id><pub-id pub-id-type="pmid">14961567</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Bieche</surname><given-names>I</given-names></name><name><surname>de Murcia</surname><given-names>G</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><article-title>Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer</article-title><source>Clin Cancer Res</source><year>1996</year><volume>2</volume><fpage>1163</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">9816283</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>JJ</given-names></name><name><surname>Roush</surname><given-names>GC</given-names></name><name><surname>Dubin</surname><given-names>N</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Roses</surname><given-names>DF</given-names></name><name><surname>Harris</surname><given-names>MN</given-names></name><article-title>Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis</article-title><source>Pharmacogenetics</source><year>1997</year><volume>7</volume><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1097/00008571-199708000-00006</pub-id><pub-id pub-id-type="pmid">9295059</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Rajaee-Behbahani</surname><given-names>N</given-names></name><name><surname>Schmezer</surname><given-names>P</given-names></name><name><surname>Ramroth</surname><given-names>H</given-names></name><name><surname>Burkle</surname><given-names>A</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name><name><surname>Dietz</surname><given-names>A</given-names></name><name><surname>Becher</surname><given-names>H</given-names></name><article-title>Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study</article-title><source>Int J Cancer</source><year>2002</year><volume>98</volume><fpage>780</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1002/ijc.10234</pub-id><pub-id pub-id-type="pmid">11920651</pub-id></mixed-citation></ref></ref-list></back></article>